Impact of newborn screening and quality of therapy on the neurological outcome in glutaric aciduria type 1: a meta-analysis

Glutaric aciduria type 1 (GA1), a rare inherited neurometabolic disorder, results in a complex movement disorder (MD) with predominant dystonia if untreated. Implementation into newborn screening (NBS) programs and adherence to recommended therapy are thought to improve the neurological outcome.

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Boy, Nikolas (VerfasserIn) , Mengler, Katharina (VerfasserIn) , Heringer-Seifert, Jana (VerfasserIn) , Hoffmann, Georg F. (VerfasserIn) , Garbade, Sven (VerfasserIn) , Kölker, Stefan (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2021
In: Genetics in medicine
Year: 2021, Jahrgang: 23, Heft: 1, Pages: 13-21
ISSN:1530-0366
DOI:10.1038/s41436-020-00971-4
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41436-020-00971-4
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41436-020-00971-4
Volltext
Verfasserangaben:Nikolas Boy, MD, Katharina Mengler, MD, Jana Heringer-Seifert, MD, Georg F. Hoffmann, MD, Sven F. Garbade, PhD and Stefan Kölker, MD
Beschreibung
Zusammenfassung:Glutaric aciduria type 1 (GA1), a rare inherited neurometabolic disorder, results in a complex movement disorder (MD) with predominant dystonia if untreated. Implementation into newborn screening (NBS) programs and adherence to recommended therapy are thought to improve the neurological outcome.
Beschreibung:Published: 28 September 2020
Gesehen am 27.10.2021
Beschreibung:Online Resource
ISSN:1530-0366
DOI:10.1038/s41436-020-00971-4